Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Forxiga (dapagliflozin) for Treatment of Type 2 Diabetes

Drug (Brand / Generic)

Forxiga / dapagliflozin

Company / Licensee

AstraZeneca and Bristol-Myers Squibb

Therapy Class

SGLT2 inhibitor

Current Indication

Type 2 diabetes

Market Sector

Diabetes

Development Status

Approved in Europe, Australia, Brazil, Mexico, New Zealand, and the US
Expand
Close
Close
Close

Go Top